Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and meaningful, especially for those of you who managed to survive the annual trek to the J.P. Morgan conference. Now that all the excitement is in the rear view mirror, the time has come to focus on the tasks ahead — meetings, deadlines, and the usual what-not. So please join us as we reach for a needed cup of stimulation and dig in for another busy day. Hope yours goes well and, of course, do keep in touch. We appreciate the tips and insights. …

Sen. Cory Booker (D-N.J.) is trying to overcome doubts that he is too close to the pharmaceutical industry ahead of an expected presidential campaign, The Hill says. The progressive criticism reached a crescendo in early 2017 when he voted against a budget amendment calling for importing drugs from abroad. But last week, Booker attempted to show he is tough on drug companies, appearing alongside Sen. Bernie Sanders (I-Vt.), a potential presidential rival, at a press conference on lowering drug prices.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy